Conversely, CRIPTO1-overexpressing primary EGFRM+ NSCLC cells that were intrinsically erlotinib-resistant became TKI-sensitive upon silencing of CRIPTO1 expression [215]. Here, CRIPTO is linked to non-small cell lung carcinoma.